Camurus

Lund, Sweden - 24 July 2025 - Camurus (NASDAQ STO: CAMX) today informs that the Chief Executive Officer Fredrik Tiberg has sold 115,000 shares in the company, representing approximately 7 percent of his total shareholdings. Following the transaction, Fredrik Tiberg owns 1.5 million shares and remains one of the company's largest shareholders.

The transaction is reported to the Swedish Financial Supervisory Authority in accordance with applicable regulations.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)70 682 1587
fredrik.tiberg@camurus.com

Anders Vadsholt, Chief Financial Officer
Tel. +46 (0)70 161 26 86
ir@camurus.com

About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal^® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.

This information was submitted for publication at 7:20 pm CET on 24 July 2025.